```html

Zollinger‑Ellison Syndrome (Type 1) – Comprehensive Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that arise in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and other gastrointestinal problems.

Type 1 ZES refers specifically to the sporadic (non‑inherited) form that accounts for roughly 70‑80 % of all Zollinger‑Ellison cases. The remaining 20‑30 % are type 2 (associated with multiple endocrine neoplasia type 1, MEN‑1) or type 3 (sporadic, often malignant, but not linked to MEN‑1).

• Who it affects: Typically adults 30–60 years old; slight female predominance (≈55 %).
• Prevalence: Overall ZES occurs in about 1 case per 1 million people worldwide. Type 1 makes up 0.7–0.8 cases per million.
• Geography: No clear regional differences; cases are reported worldwide.

Symptoms

The hallmark of ZES is acid‑related gastrointestinal distress, but the presentation can be variable. Symptoms may develop gradually and are often mistaken for ordinary ulcer disease.

Gastro‑intestinal Symptoms

• Recurrent or refractory peptic ulcers – especially multiple ulcers in the duodenum, jejunum, or even the esophagus.
• Abdominal pain – crampy, often worsens 1–3 hours after meals.
• Diarrhea – watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
• Heartburn/acid reflux – chronic gastro‑esophageal reflux disease (GERD) due to high acid load.
• Nausea & vomiting – can be triggered by ulcer perforation or intestinal obstruction.
• Weight loss – secondary to malabsorption, chronic diarrhea, and anorexia.

Systemic/Other Symptoms

• Fatigue – from anemia or chronic illness.
• Upper‑GI bleeding – melena or hematemesis from ulcer erosion.
• Gastroparesis – delayed gastric emptying occasionally reported.
• Kidney stones – hypercalciuria can accompany gastrin excess.

Causes and Risk Factors

Zollinger‑Ellison syndrome type 1 is not inherited; it arises from somatic mutations that cause a neuroendocrine tumor (NET) to produce gastrin.

Pathophysiology

• Mutations in the MEN1 gene, KRAS, or SMAD4 have been identified in a subset of sporadic gastrinomas, but most cases lack a clear genetic driver.
• Excess gastrin → parietal cell hyperstimulation → >10‑fold increase in gastric HCl secretion.
• Acid hypersecretion overwhelms bicarbonate buffers, leading to mucosal injury and ulcer formation.

Risk Factors

• Age 30–60 years (peak incidence).
• Male or female (slightly more common in women).
• Smoking – may increase risk of gastric ulcer disease, though direct link to gastrinoma formation is unclear.
• Family history of NETs – raises suspicion, but does not cause type 1 specifically.

Diagnosis

Because symptoms mimic common ulcer disease, a high index of suspicion is essential, especially when ulcers are multiple, recurrent, or located beyond the duodenum.

Step‑by‑step Diagnostic Approach

1. Clinical assessment – detailed history, medication review (e.g., NSAID use), and physical exam.
2. Laboratory tests
   • Fasting serum gastrin level – >1000 pg/mL (normal < 100 pg/mL) is highly suggestive; levels 2–3 × upper limit with gastric pH < 2 may also be diagnostic.
   • Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) confirms ZES when basal gastrin is equivocal.
   • Basic metabolic panel – evaluate electrolytes, calcium, renal function.
   • Complete blood count – look for anemia from chronic bleeding.
3. Imaging studies
   • CT scan (multiphase abdomen) – detects pancreatic/duodenal masses ≥ 1 cm.
   • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, including small gastrinomas.
   • Endoscopic ultrasound (EUS) – excellent for lesions < 1 cm and for fine‑needle aspiration biopsy.
   • Upper endoscopy (EGD) – visualizes ulcer disease, allows biopsies to rule out H. pylori or malignancy.
4. Histopathology – biopsy of the tumor confirms neuroendocrine nature (chromogranin A, synaptophysin positive) and assesses Ki‑67 proliferation index for grading.

Guidelines from the Mayo Clinic and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recommend these steps to avoid misdiagnosis.

Treatment Options

Therapy aims to control acid hypersecretion, eradicate ulcer disease, and remove or control the gastrinoma.

Medical Management

• Proton pump inhibitors (PPIs) – high‑dose omeprazole (40–80 mg daily) or esomeprazole (40–80 mg daily) are first‑line. PPIs normalize gastric pH, heal ulcers, and relieve symptoms in > 90 % of patients.
• H2‑receptor antagonists – used as adjuncts when PPIs alone are insufficient.
• Somatostatin analogues (octreotide or lanreotide) – bind somatostatin receptors on gastrinomas, decreasing gastrin secretion and sometimes shrinking tumor size.
• Antibiotic therapy for H. pylori – if infection is present, eradication improves ulcer healing.

Surgical Options

• Localized tumor resection – preferred if imaging shows a solitary gastrinoma (< 2 cm) without metastasis. Pancreaticoduodenectomy (Whipple) may be required for duodenal lesions.
• Enucleation – removal of small, well‑encapsulated tumors while preserving pancreatic tissue.
• Liver metastasectomy – considered when hepatic spread is limited.
• Debulking surgery – reduces tumor burden to improve symptom control when cure is not possible.

Interventional & Systemic Therapies

• Radiofrequency ablation (RFA) or cryo‑ablation – for isolated liver metastases.
• Targeted therapies – everolimus or sunitinib have activity against well‑differentiated neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to tumor cells expressing somatostatin receptors; shown to improve progression‑free survival.

Lifestyle & Supportive Measures

• Small, frequent meals low in fat and acid‑triggering foods.
• Avoid NSAIDs, aspirin, and alcohol, which exacerbate ulcer formation.
• Quit smoking – improves ulcer healing and overall prognosis.
• Maintain adequate hydration, especially if diarrhea is prominent.

Living with Zollinger‑Ellison Syndrome (Type 1)

Chronic management focuses on symptom control, monitoring for tumor progression, and maintaining quality of life.

Daily Management Tips

• Medication adherence – take PPIs exactly as prescribed; missing doses can cause rebound acid hypersecretion.
• Monitor symptoms – keep a diary of pain, stool frequency, and any bleeding signs.
• Regular follow‑up – at least every 3–6 months for labs (gastrin, chromogranin A) and imaging annually or sooner if symptoms change.
• Nutritional support – consider a dietitian visit to address malabsorption; supplement fat‑soluble vitamins (A, D, E, K) if steatorrhea persists.
• Vaccinations – patients on somatostatin analogues or systemic therapies may be immunocompromised; keep hepatitis B, influenza, and COVID‑19 vaccines up‑to‑date.
• Psychosocial care – chronic disease can cause anxiety; support groups or counseling are beneficial.

Surveillance Strategy

1. Fasting gastrin level every 6 months.
2. Cross‑sectional imaging (CT or MRI) annually.
3. Somatostatin receptor imaging every 2–3 years or if new symptoms appear.
4. Endoscopic evaluation of ulcer healing 6–12 weeks after initiating high‑dose PPI therapy.

Prevention

Because type 1 ZES arises from sporadic mutations, primary prevention is limited. However, lifestyle measures can reduce the risk of ulcer complications and possibly slow tumor progression.

• Avoid chronic Helicobacter pylori infection – test and treat if positive.
• Limit exposure to gastric irritants – NSAIDs, excessive alcohol, and tobacco.
• Regular medical check‑ups – early detection of persistent ulcer disease leads to earlier diagnosis of ZES.

Complications

If untreated or inadequately controlled, Zollinger‑Ellison syndrome can lead to serious health problems:

• Perforated peptic ulcer – requires emergency surgery; mortality up to 20 % in delayed cases.
• Massive gastrointestinal bleeding – may cause anemia, hypovolemic shock.
• Intestinal obstruction – from ulcer scarring or tumor growth.
• Malabsorption and nutritional deficiencies – chronic diarrhea leads to weight loss, osteoporosis, and electrolyte imbalances.
• Metastatic disease – up to 30 % of type 1 gastrinomas develop liver metastases over time.
• Gastric carcinoid tumors – driven by chronic hypergastrinemia; may become malignant.
• Reduced quality of life – chronic pain, frequent medication, and surveillance can affect daily activities.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – NIDDK, American College of Gastroenterology, World Health Organization (WHO), Cleveland Clinic, & peer‑reviewed journals (e.g., Journal of Clinical Endocrinology & Metabolism, 2022; Gastroenterology, 2023).

```